Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net margin is calculated as Net Income divided by its Revenue. TherapeuticsMD's Net Income for the
three
months ended in Mar. 2026 was $0.10 Mil. TherapeuticsMD's Revenue for the
three
months ended in Mar. 2026 was $0.72 Mil. Therefore, TherapeuticsMD's net margin for the quarter that ended in Mar. 2026 was 13.12%.
The historical rank and industry rank for TherapeuticsMD's Net Margin % or its related term are showing as below:
TXMD'
s Net Margin % Range Over the Past 10 Years
Min: -6700.93 Med: -406.64 Max: 160.08
Current: 5.34
TXMD's Net Margin % is ranked better than 50% of 960
companies
in the Drug Manufacturers industry
Industry Median: 5.33
vs TXMD: 5.34
TherapeuticsMD (NAS:TXMD) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
TherapeuticsMD Net Margin % Related Terms
TherapeuticsMD Net Margin % Historical Data
* Premium members only.
The historical data trend for TherapeuticsMD's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TherapeuticsMD Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Net Margin % distribution charts can be found below:
* The bar in red indicates where TherapeuticsMD's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TherapeuticsMD (TXMD) has a Net Margin % of 13.12% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on TherapeuticsMD and its competitors. According to the industry distribution chart, TherapeuticsMD ranks #480 out of 960 companies in the Drug Manufacturers industry, placing it in the top 50%.
Is TherapeuticsMD's Net Margin % too high?
TherapeuticsMD's current Net Margin % is 13.12%. The Drug Manufacturers industry median Net Margin % is 5.33. TherapeuticsMD's value of 13.12% is 146.2% above this industry median. Based on the distribution chart, TherapeuticsMD ranks #480 out of 960 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, TherapeuticsMD has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TherapeuticsMD's Net Margin % compare to AYTU and MRMD?
According to the Drug Manufacturers industry distribution chart, TherapeuticsMD ranks #480 out of 960 companies for Net Margin %. This puts TherapeuticsMD in the upper half of its industry. The industry median Net Margin % is 5.33. TherapeuticsMD's value of 13.12% is 146.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.33, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TherapeuticsMD's current Net Margin % of 13.12% is 146.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on TherapeuticsMD and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TherapeuticsMD's current Net Margin % is 13.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TherapeuticsMD stock overvalued right now?
Based on GuruFocus' analysis, TherapeuticsMD (TXMD) is currently considered Fairly Valued. The stock's GF Value™ is $2.02, compared to a current price of $2.09 — trading 3.2% above its estimated fair value. The current Net Margin % is 13.12% and 146.2% above the Drug Manufacturers industry median of 5.33. TherapeuticsMD's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For TherapeuticsMD (TXMD), the current Net Margin % is 13.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TherapeuticsMD (TXMD) Overvalued in 2026?
Based on GuruFocus' analysis, TherapeuticsMD stock appears to be overvalued.
The current stock price of $2.09 is trading 3.2% above its estimated GF Value™ of $2.02.
GuruFocus considers TherapeuticsMD to be Fairly Valued.
Key valuation signals for TXMD:
Net Margin %: 13.12%
GF Value™: $2.02 vs. price of $2.09 (3.2% above fair value)
Industry Position: 146.2% above the Drug Manufacturers median (#480 of 960)
No single metric tells the full story. See the TXMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
56GF Score
Get the complete analysis for TXMD
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXMD has been successfully added to your 
